- Home
- CRDF vs ACRS Comparison
CRDF vs ACRS Comparison
Compare CRDF & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- ACRS
- Stock Information
- Founded
- CRDF 1999
- ACRS 2012
- Country
- CRDF United States
- ACRS United States
- Employees
- CRDF N/A
- ACRS N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- ACRS Biotechnology: Pharmaceutical Preparations
- Sector
- CRDF Health Care
- ACRS Health Care
- Exchange
- CRDF Nasdaq
- ACRS Nasdaq
- Market Cap
- CRDF 144.4M
- ACRS 165.7M
- IPO Year
- CRDF N/A
- ACRS 2015
- Fundamental
- Price
- CRDF $2.00
- ACRS $1.88
- Analyst Decision
- CRDF Strong Buy
- ACRS Strong Buy
- Analyst Count
- CRDF 5
- ACRS 9
- Target Price
- CRDF $11.10
- ACRS $9.25
- AVG Volume (30 Days)
- CRDF 1.1M
- ACRS 813.5K
- Earning Date
- CRDF 11-06-2025
- ACRS 11-05-2025
- Dividend Yield
- CRDF N/A
- ACRS N/A
- EPS Growth
- CRDF N/A
- ACRS N/A
- EPS
- CRDF N/A
- ACRS N/A
- Revenue
- CRDF $545,000.00
- ACRS $16,789,000.00
- Revenue This Year
- CRDF N/A
- ACRS N/A
- Revenue Next Year
- CRDF N/A
- ACRS N/A
- P/E Ratio
- CRDF N/A
- ACRS N/A
- Revenue Growth
- CRDF N/A
- ACRS N/A
- 52 Week Low
- CRDF $1.90
- ACRS $1.05
- 52 Week High
- CRDF $5.64
- ACRS $5.17
- Technical
- Relative Strength Index (RSI)
- CRDF 48.21
- ACRS 50.09
- Support Level
- CRDF N/A
- ACRS $2.01
- Resistance Level
- CRDF $2.27
- ACRS $2.16
- Average True Range (ATR)
- CRDF 0.11
- ACRS 0.11
- MACD
- CRDF -0.04
- ACRS -0.03
- Stochastic Oscillator
- CRDF 87.89
- ACRS 24.32
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.